Re: James P. Buteau, Daniel Moon, Michael T. Fahey, et al. Effect of [68Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Clinically High-risk Non-suspicious Findings on Multiparametric MRI (PRIMARY2): A Multicenter, Non-inferiority, Phase 3, Randomized Controlled Trial. Lancet Oncol 2026;27:839-848

doi:10.1016/j.eururo.2026.07.011

Re: James P. Buteau, Daniel Moon, Michael T. Fahey, et al. Effect of [68Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Clinically High-risk Non-suspicious Findings on Multiparametric MRI (PRIMARY2): A Multicenter, Non-inferiority, Phase 3, Randomized Controlled Trial. Lancet Oncol 2026;27:839-848

Journal: European urology (Q1)
Published: 23 July 2026
Study design: Narrative review / expert opinion
Evidence level: Level 1, High (CEBM 1b)
Authors: Alessandro Uleri, Michael Baboudjian, Giovanni Lughezzani, Guillaume Ploussard
PMID: 42493339
DOI: 10.1016/j.eururo.2026.07.011

Why clinicians should know about it

Picked for Radiology, Radiation Oncology, Nuclear Medicine, Medical Physics and Imaging (top studies of the week, 26 July 2026).

View on PubMed Full text at the publisher Open in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.